Skip to main content

Coronavirus (COVID-19): Visitor Restrictions, Resources, and Updates

Explore URMC
menu
URMC / Research / Clinical Trials / Study Details

MGD007 Combined With MGA012 in Relapsed/Refractory Metastatic Colorectal Cancer

Research Question:
What is the safety, tolerability, and maximum tolerated dose (MTD) of MGD007 when combined with MGA012? And what are the pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD), and the anti-tumor activity of the combination of MGD007 and MGA012?

Basic Study Information

Purpose:
This study is designed to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary anti-tumor activity of MGD007 and MGA012, administered in combination by IV infusion, in patients with relapsed/refractory metastatic colorectal carcinoma. The study consists of a Dose Escalation Phase to determine the Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) - MAD; if no MTD is defined - of the drug combination, followed by a Cohort Expansion Phase to further define the safety and initial anti-tumor activity of the drug combination with the doses established in the Dose Escalation Phase.

Location: University of Rochester Medical Center
Study Reference #: IGIC18049

Lead Researcher (Principal Investigator)

Lead Researcher:  Marcus Noel

Study Contact Information

Study Coordinator: Tanya Smith
Phone: (585) 275-8213
Email: Tanya_Smith@URMC.Rochester.edu

Additional Study Details

Return to Search